MedPath

A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Phase 1
Active, not recruiting
Conditions
Lymphoma, Non-Hodgkin
Leukemia, Lymphocytic, Chronic, B-Cell
Interventions
Drug: JNJ-75348780
Registration Number
NCT04540796
Lead Sponsor
Janssen Research & Development, LLC
Brief Summary

The purpose of this study is to characterize safety and to determine the putative recommended Phase 2 dose(s) (RP2D\[s\]) and optimal dosing schedule(s) of JNJ-75348780 in participants with relapsed/ refractory B-cell Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) in Part A and to further characterize the safety at the RP2D(s) in Part B.

Detailed Description

B-cell lymphoid malignancies include CLL and NHL and are defined by clonal populations of B-lymphocytes expressing identical surface antigens. CD22 is a surface protein specifically expressed on B-lymphocytes and is expressed in B-lymphocytic malignancies. It is known to negatively regulate the B-cell receptor via its cytosolic immunoreceptor tyrosine-based inhibitory motifs. JNJ-75348780 is a novel human bispecific antibody that recognizes the CD3 antigen on T-lymphocytes and the CD22 antigen on mature and malignant B-lymphocytes. JNJ-75348780 is hypothesized to lead to cytotoxicity, T-cell activation, and induction of cytokines upon engagement of CD3 on T-cells and CD22 on malignant B-lymphocytes. The study consists of screening phase, treatment phase and post-treatment phase. The total study duration will be up to 2 years 10 months. Efficacy assessments will include radiographic image assessments, positron emission tomography scan, bone marrow assessment, endoscopy or colonoscopy, physical examinations. Safety will be monitored throughout the study.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
147
Inclusion Criteria
  • Histologic documentation of disease: B-cell NHL or CLL requiring therapy; All participants must have relapsed or refractory disease with no other approved therapies available that would be more appropriate in the investigator's judgment. B cell NHL as defined per the 2016 World Health Organization (WHO) classification: In addition, the following disease-specific criteria outlined below must be met a) If diffuse large B-cell lymphoma (DLBCL): received, or not eligible for high-dose chemotherapy and autologous stem cell transplantation with curative intent, b) If follicular lymphoma (FL)/ marginal zone lymphoma (MZL) (except mucosa-associated lymphoid tissue [MALT]), or Waldenstrom macroglobulinemia (WM): previously treated with a minimum of 2 prior lines of systemic therapy, with at least 1 prior line containing an anti-CD20 antibody, c) If mantle cell lymphoma (MCL): previously treated with at least 1 prior line of systemic therapy containing an anti-CD20 antibody. CLL or small lymphocytic lymphoma (SLL): relapsed or refractory with at least 2 prior lines of therapy to include a bruton tyrosine kinase inhibitor (BTKi) and/or a B-cell lymphoma (BCL)2 inhibitor, if eligible. For Part B: participants must have measurable disease as defined by the appropriate disease response criteria
  • Eastern Cooperative Oncology Group (ECOG) performance status Grade of 0 or 1
  • Cardiac parameters within the following range: corrected QT interval (QTc intervals corrected using Fridericia's formula [QTcF]) less than or equal to (<=) 480 milliseconds (ms) based on the average of triplicate assessments performed no more than 5 (plus minus [+ -] 3) minutes apart
  • Women of childbearing potential must have a negative highly sensitive serum pregnancy test (Beta human chorionic gonadotropin) at screening and prior to the first dose of study drug
  • Women must be: a) not of childbearing potential, b) of childbearing potential and practicing a highly effective, preferably user independent method of contraception (failure rate of less than (<) 1 percent (%) per year when used consistently and correctly) and agrees to remain on a highly effective method while receiving study drug and until 90 days after last dose
Read More
Exclusion Criteria
  • Known central nervous system (CNS) involvement with lymphoma
  • Prior solid-organ transplantation
  • Either of the following: a) received an autologous stem cell transplant <=3 months before the first dose of JNJ 75348780, b) prior treatment with allogenic stem cell transplant <= 6 months before the first dose of JNJ-75348780, or has evidence of graft versus host disease that requires immunosuppressant therapy
  • Prior chemotherapy, targeted therapy, immunotherapy or radiotherapy (with the exclusion of palliative radiation to limited sites that do not interfere with response assessment based on a sufficient number of other sites), within 2 weeks before the first administration of study drug. For investigational agents where the half-life is known, there should be a treatment-free window of at least 2 weeks or 5 half-lives, whichever is longer. For investigational agents with long half-lives a wash-out of 4 weeks is acceptable. Participants who received prior treatment with anti-CD20 * anti-CD3 bispecific therapy will be excluded until a dedicated cohort(s) is opened as determined by the SET
  • Active autoimmune disease that requires systemic immunosuppressive medications (example, chronic corticosteroid, methotrexate, or tacrolimus)
  • History of malignancy (other than the disease under study in the cohort to which the participant is assigned) within 1 year prior to the first administration of study drug. Exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy which in the opinion of the investigator, with concurrence with the sponsor's medical monitor, is considered cured with minimal risk of recurrence within 1 year before the first dose of study drug. Concomitant malignancies that are unlikely to progress and/or preclude evaluation of study endpoints may be allowed after discussion with the Study Responsible Physician
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SEQUENTIAL
Arm && Interventions
GroupInterventionDescription
Part B: Cohort ExpansionJNJ-75348780Participants will receive JNJ-75348780 at one of the putative RP2Ds determined in Part A.
Part A: Dose EscalationJNJ-75348780Participants will receive JNJ-75348780. The dose levels will be escalated sequentially based on the decisions of the Study Evaluation Team (SET), along with the potential exploration of other routes of administration and schedules, until one or more recommended Phase 2 Doses (RP2D) have been identified.
Primary Outcome Measures
NameTimeMethod
Part A and Part B: Number of Participants with Dose-Limiting Toxicity (DLT)Up to 28 days

Number of participants with DLT will be assessed. The DLTs are specific adverse events and are defined as any of the following: high grade non-hematologic toxicity, or hematologic toxicity.

Part A and Part B: Number of Participants with Adverse Events (AEs) as a Measure of Safety and TolerabilityUp to 2 years 10 months

An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.

Part A and Part B: Number of Participants with AEs by SeverityUp to 2 years 10 months

Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening, and Grade 5= Death related to adverse event.

Secondary Outcome Measures
NameTimeMethod
Minimum Observed Serum Concentration (Cmin) of JNJ-75348780Predose, 48 hours postdose (up to 2 years 10 months)

Cmin is the minimum observed serum concentration of JNJ-75348780.

Maximum Observed Serum Concentration (Cmax) of JNJ-75348780Predose, 48 hours postdose (up to 2 years 10 months)

Cmax is the maximum observed serum concentration of JNJ-75348780.

Complete Response (CR) RateUp to 2 years 10 months

CR rate is defined as the percentage of participants who achieve a best response of CR according to the revised response criteria for malignant lymphoma, iwCLL response criteria and IWWM response criteria.

Area Under the Concentration-time Curve From Time Zero to End of Dosing Interval (AUCtau) of JNJ-75348780Up to 2 years 10 months

AUCtau is the measure of the serum drug concentration from time zero to end of dosing interval.

Objective Response Rate (ORR)Up to 2 years 10 months

ORR is defined as the percentage of participants who achieve a partial response (PR) or better according to the revised response criteria for malignant lymphoma, the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) response criteria and International Workshop for Waldenstrom Macroglobulinemia (IWWM) response criteria.

Time to Response (TTR)Up to 2 years 10 months

TTR is defined for participants who achieved PR or CR as the time from the first dose of study drug to first response of PR or CR according to the revised response criteria for malignant lymphoma, iwCLL response criteria and IWWM response criteria.

Duration of Response (DOR)Up to 2 years 10 months

DOR is defined for participants who achieved PR or CR as the time between the date of initial documentation of PR or CR to the date of either the first documented evidence of disease progression or death according to the revised response criteria for malignant lymphoma, iwCLL response criteria and IWWM response criteria.

Trial Locations

Locations (32)

Austin Hospital

🇦🇺

Heidelberg, Australia

The Catholic University of Korea Seoul St Marys Hospital

🇰🇷

Seoul, Korea, Republic of

Sheba Medical Center

🇮🇱

Ramat Gan, Israel

The Christie Nhs Foundation Trust

🇬🇧

Manchester, United Kingdom

Carmel Medical Center

🇮🇱

Haifa, Israel

Tel Aviv Sourasky MC

🇮🇱

Tel Aviv, Israel

CHRU de Lille Hopital Claude Huriez

🇫🇷

Lille, France

Plymouth Hospital NHS Trust

🇬🇧

Plymouth, United Kingdom

Clinica Univ. de Navarra

🇪🇸

Pamplona, Spain

Hosp Clinico Univ de Salamanca

🇪🇸

Salamanca, Spain

Hosp Univ Fund Jimenez Diaz

🇪🇸

Madrid, Spain

Severance Hospital Yonsei University Health System

🇰🇷

Seoul, Korea, Republic of

Linear Clinical Research Ltd

🇦🇺

Nedlands, Australia

Hospital de Vall D'Hebron

🇪🇸

Barcelona, Spain

Centre hospitalier Lyon-Sud

🇫🇷

Pierre Benite, France

Leicester Royal Infirmary

🇬🇧

Leicester, United Kingdom

CHU Nantes

🇫🇷

NANTES Cedex 1, France

Chang-Gung Memorial Hospital, Kaohsiung

🇨🇳

Kaohsiung, Taiwan

Hosp. Univ. Germans Trias I Pujol

🇪🇸

Barcelona, Spain

Kings College Hospital

🇬🇧

London, United Kingdom

Seoul National University Hospital

🇰🇷

Seoul, Korea, Republic of

Samsung Medical Center

🇰🇷

Seoul, Korea, Republic of

Hadassah Medical Center

🇮🇱

Jerusalem, Israel

Rambam Medical Center

🇮🇱

Haifa, Israel

Icahn School of Medicine at Mount Sinai

🇺🇸

New York, New York, United States

National Taiwan University Hospital

🇨🇳

Taipei, Taiwan

Taichung Veterans General Hospital

🇨🇳

Taichung, Taiwan

China Medical University Hospital

🇨🇳

Taichung, Taiwan

University of Alabama at Birmingham

🇺🇸

Birmingham, Alabama, United States

The University of Texas MD Anderson Cancer Center

🇺🇸

Houston, Texas, United States

Asan Medical Center

🇰🇷

Seoul, Korea, Republic of

National Cheng Kung University Hospital

🇨🇳

Tainan, Taiwan

© Copyright 2025. All Rights Reserved by MedPath